Cowan-Jacob Sandra W, Fendrich Gabriele, Manley Paul W, Jahnke Wolfgang, Fabbro Doriano, Liebetanz Janis, Meyer Thomas
Discovery Technologies, Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland.
Structure. 2005 Jun;13(6):861-71. doi: 10.1016/j.str.2005.03.012.
The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have determined the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail. This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe. NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as observed for Abl, suggesting that c-Src may also be regulated by myristate binding. In addition, the structure contains a des-methyl analog of the antileukemia drug imatinib (STI571; Gleevec). This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.
Abl和Src家族酪氨酸激酶活性的调节是由SH3、SH2和激酶(SH1)结构域之间的分子内相互作用介导的。我们已经确定了c-Src未磷酸化形式的晶体结构,其中SH2结构域不与C末端尾巴结合。这导致了一种开放结构,其中激酶结构域采用活性构象,C末端结合在C末端叶的疏水口袋内。核磁共振结合研究支持这样的假设,即如Abl中观察到的那样,N末端肉豆蔻酸可以结合在这个口袋中,这表明c-Src也可能受肉豆蔻酸结合的调节。此外,该结构包含抗白血病药物伊马替尼(STI571;格列卫)的去甲基类似物。该结构揭示了为什么该药物对活性激酶构象显示出低亲和力,这有助于其优异的激酶选择性谱。